Ready to Leverage AI for Clinical Data Analytics? You’ll Need These 3 Things.

Over the past few years, I’ve had countless conversations with biopharma leaders about the intersection of AI strategy, clinical data, and enterprise transformation. Organizations are charging toward AI deployment with real ambition and real budget. What varies is readiness. When you look beneath the vision, you find that readiness has three distinct layers, the data foundation underneath the model, the governance system around it and the culture of the people expected to use it. Most organizations have made serious progress on one. Very few have built all three. Almost none have built them on the same timeline, which is the part that matters most. 

That gap may help explain the divide identified in MIT Media Lab’s Project NANDA published report “The GenAI Divide: State of AI in Business 2025” which draws on more than 300 public AI initiatives. The researchers found that only about 5% of integrated GenAI pilots were producing substantial, measurable value. 

It’s worth highlighting that this report has received some pushback from the industry, notably for its claim that 95% of AI pilots produced no measurable impact. Critics argue that in a substantial number of the initiatives cited in the report, the pilot never established a pre-deployment baseline. There was nothing against which impact could be measured. While this is a fair criticism, I think it’s important to note that the 95% statistic—while not hard evidence that AI does not work in the enterprise—is evidence that most organizations deployed their AI pilot without the scaffolding required to know whether it worked. 

What’s the disconnect between AI theory and AI practice? What three layers do biopharma companies need to effectively leverage AI in clinical trials and why are these layers so hard to apply?  

1. An AI-Ready Data Foundation  

The clinical AI use cases that have genuinely broken out of pilot mode share one characteristic: clean, verifiable data that fits naturally into how scientists and clinicians already work. The ones running as perpetual pilots are stuck because the data underneath them is fragmented, incomplete, and hard to validate. 

“Garbage in, garbage out” isn’t a new maxim, so why are companies still struggling with their data foundation layer?  

The volume pressure is real and increasing. Research from Tufts CSDD and TransCelerate found that an average Phase III protocol now collects roughly 5.9 million datapoints, growing about 11 percent annually since 2020, against fewer than one million a little over a decade ago. 

But volume is the easier half of the problem. The harder half of this story is that most biopharma organizations have not yet solved the data problem because their data sits in systems never designed to speak to one another: a CTMS that does not reconcile against the EDC, safety data in one warehouse and clinical data in another, lab and ePRO feeds arriving on different standards and different times. 

You can put the most sophisticated AI model in the world on top of that architecture. It will produce confident-sounding outputs from incomplete inputs. In a regulatory environment, an output you cannot trace back to a validated source cannot support submission, no matter how good the answer looks. This is the wall most pilots hit, and so projects don’t move beyond their pilots.  

2. A Functional Governance System 

To make governance work in practice, not just on paper, it must address questions like: Which data sources are validated for use in a regulatory submission? Which model outputs can a medical reviewer act on, and which require human verification? When a model is updated, what re-validation is required and how fast can it happen? Who owns a decision when an AI agent recommended that a human accepted? 

Most organizations cannot answer these questions precisely. The result is that AI pilots that get deployed do so with informal, ad hoc guardrails. But without proper guardrails, audit logs, coded constraints, and validated workflows, agentic AI can add significant risk in clinical environments. Often, pilots don’t get deployed at all because the risk feels unmanageable.  

3. A Culture of Innovation 

Medical reviewers, clinical data scientists, and biostatisticians are the people with the deepest understanding of clinical data, and they are increasingly arriving at the table with a clear demand: I want to talk to the data. I don’t want to learn another interface. 

Agentic AI is reaching production maturity in life sciences. Meanwhile, clinical data environments, with their regulatory requirements, validation obligations, and audit trail demands, are more complex. This creates genuine tension for any organization and SaaS platform trying to manage the transition to agentic AI responsibly. We’re seeing a cultural gap widening between what sophisticated users expect and what organizations can currently offer them in a compliant, validated form.  

The organizations that manage that gap well will create a culture of AI innovation and retain the talent and the trust that make AI adoption stick. The ones that don’t will watch their best scientific minds route around the system entirely, pasting proprietary data into personal AI tools, building undocumented analysis in local notebooks that create exactly the governance problems they were trying to avoid. 

Uniting the Points of the AI Triangle 

The three layers, data, governance, and culture must be designed as one connected operating model, because any two of them without the third fails. 

That starts with bringing clinical data together in a form that is standardized, traceable, and ready for analysis. Organizations need a data foundation that connects information across the clinical ecosystem while preserving lineage, validation, and auditability. 

When it comes to governance, the rules governing which data can be used, which outputs require human review, and how decisions are documented should be built into the workflows where AI is applied. This allows teams to move faster without forcing them to choose between innovation and control. 

The cultural challenge becomes easier to address when the technology works the way users increasingly expect it to work. Medical reviewers, data scientists, and biostatisticians should be able to interact with clinical data in intuitive ways without bypassing validated systems or creating new compliance risks. 

What organizations will find is that these three elements scale. If they start their AI initiatives with a well-defined use case, trusted data, clear human oversight, and measurable outcomes, they can expand their AI initiatives with confidence, building on an infrastructure that supports both innovation and regulatory rigor. 

Click here learn more about the elluminate Clinical Data Intelligence Platform and how it leverages AI to accelerate clinical development.